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To investigate nephropathia epidemica in Sweden dur-
ing 1997–2007, we determined case-fatality rates for 5,282 
patients with this disease. Overall, 0.4% died of acute neph-
ropathia epidemica <3 months after diagnosis. Case-fatality 
rates increased with age. Only women showed an increased 
case-fatality rate during the ﬁ  rst year after diagnosis.
H
antaviruses cause 2 severe emerging zoonotic diseas-
es: hemorrhagic fever with renal syndrome (HFRS) 
in Eurasia and hantavirus cardiopulmonary syndrome 
(HCPS) in the Americas. These diseases have a case-fatal-
ity rate <40% depending on the speciﬁ  c hantavirus (1,2). 
Hantaviruses are primarily maintained in the environment 
by rodents, with humans serving as incidental hosts who 
are typically infected by inhalation of virus-contaminated 
rodent excreta (1,2). In parts of Europe, including Sweden, 
Puumala virus (PUUV) causes nephropathia epidemica 
(NE), a relatively mild form of HFRS with case-fatality 
rates of 0.1%–1% (1–4).
For many infectious diseases, frequency of infection 
is generally higher, and the clinical outcome often worse, 
in male patients (5–8). The reported male:female ratio for 
NE cases varies from 2 to 5:1 (1,3). Male-biased rates of 
infection have also been reported for other hantaviruses 
(1,9). However, in northern Sweden, seroprevalence does 
not differ by patient sex, which suggests the same number 
of persons of either sex might be infected with PUUV (10). 
Why males are overrepresented for diagnosed NE cases is 
not known.
We recently reported sex differences in cytokine re-
sponses during acute NE (11). Whether sexually dimorphic 
immune responses during hantavirus infection cause differ-
ences in the severity of disease between men and women 
has not been investigated. Furthermore, whether age is a 
risk factor in outcome of HFRS/HCPS is unknown. To in-
vestigate NE in Sweden during 1997–2007, we determined 
case-fatality rates for 5,282 patients with this disease.
The Study
NE is a reportable disease according to the Swedish 
Communicable Disease Act. Clinicians and microbiologic 
laboratories report diagnosed cases to the Swedish Insti-
tute for Infectious Disease Control. These notiﬁ  cations are 
stored in a database. In this study, we included all 5,282 
NE cases reported to the Swedish Institute for Infectious 
Disease Control and registered in the database during Janu-
ary 1, 1997–December 31, 2007. OpenEpi (www.openepi.
com) was used to calculate the standardized mortality ratio 
(SMR). Because NE is an acute viral infection, and as a 
comparison for the numbers of deaths during the different 
phases of NE, we used the number of deaths during the 
second year after diagnosis in the studied population.
Incidence was highest in the group 55–59 years of age 
for men and women (Figure 1, panel A), and the mean ± SD   
age at diagnosis was 49.3 ± 16.7 years for men and 50.7 ± 
16.5 years for women. The overall male:female ratio for 
NE cases was 1.52:1. Sex hormones can play major roles in 
susceptibility to infectious diseases (5,7). To test whether 
increased incidence of PUUV infection in men was depen-
dent on sex hormones, we compared sex ratios in NE cases 
between children (persons <10 years of age and presum-
ably prepubertal) and adults (>10 years of age). Sixty-two 
children were given a diagnosis of NE during 1997–2007. 
The male:female ratio for these children was 1.58:1, which 
was similar to the sex ratio for adult NE patients (1.52:1). 
This ﬁ  nding suggested that circulating sex hormones may 
not play a major role in the observed overrepresentation of 
NE in men.
Of persons with a diagnosis of NE, 21 (0.4%) patients 
died <3 months after diagnosis. The SMR was 3.5 (95% 
conﬁ  dence interval [CI] 2.22–5.26) for all patients and 6.4 
(95% CI 2.97–12.15) for female patients and 2.7 (95% CI 
1.52–4.56) for male patients during the acute phase of NE.
No persons <50 years of age died during the acute 
phase (Figure 1, panel B). However, the case-fatality rate 
increased with age (Figure 1, panel B), and the case-fa-
tality rate was 6.5% for patients >80 years of age, which 
showed age-dependent differences in mortality rates for 
NE. The mean ± SD age at time of death for patients with 
acute NE was 73.7 ± 10.4 years (range 50.9–88.5 years). 
Women died at a slightly, but not signiﬁ  cantly, younger 
mean ± SD age (71.5 ± 12.4 years, range 50.9–85.7 years, 
n = 8) than men (75.1 ± 9.2 years, range 57.8–88.5 years, 
n = 13) (p = 0.347, by t test). Mean age at time of death 
for patients with NE was 10 years less than the expected 
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life span for women and 3 years less than the expected 
life span for men (mean age at time of death in Sweden 
in 2003 was 78 years for men and 82 years for women; 
www.scb.se/statistik/_publikationer/BE0701_1986I03_
BR_BE51ST0404.pdf).
Because no patient <50 years of age died of NE dur-
ing the acute phase and the mean age at time of death was 
relatively high, we suggest that NE is rarely life threaten-
ing. To assess this possibility, we analyzed mortality rate 
patterns early after acute NE. The SMR decreased for the 
9 months after acute NE in female (SMR 0.67, 95% CI 
0.11–2.20) and male (SMR 0.36, 95% CI 0.13–0.79) pa-
tients (Figure 2).
We also analyzed SMRs for the ﬁ  rst year (including 
the acute phase of NE [<3 months after diagnosis] and early 
phase [3–12 months] after NE diagnosis). For 52 persons 
who died <2 years after NE diagnosis, the case-fatality rate 
was only slightly higher in the ﬁ  rst year (n = 28) than in 
the second year (n = 24) after diagnosis (SMR 1.17, 95% 
CI 0.79–1.66). A clear difference was observed between   
men and women. Deaths did not increase in men between 
the ﬁ  rst (n = 18) and second (n = 19) years after diagnosis 
(SMR 0.95, 95% CI 0.58–1.49). However, we observed a 
2× difference in deaths for women between the ﬁ  rst (n = 
10) and second (n = 5) years after diagnosis (SMR 2.0, 95% 
CI 1.02–3.57).
Conclusions
We report an age-dependent case-fatality rate for the 
hantavirus disease NE; most deaths occurred in older per-
sons. There is a report of patients <50 years of age dying 
of NE (12), but this ﬁ  nding is rare. Increased case-fatality 
rates in older persons have been described for other in-
fectious diseases. For example, during a typical inﬂ  uenza 
season, 90% of deaths caused by inﬂ  uenza occur among 
persons >65 years of age (13). Whether this ﬁ  nding is 
unique to relatively mild infection with PUUV or is a con-
served feature of all hantaviruses causing HFRS/HCPS is 
unknown.
We previously showed that there are sex differences in 
cytokine responses during acute NE (11), which suggested 
that there might be sex differences in severity of infection. 
Women showed a 2× difference in number of deaths be-
tween the ﬁ  rst year and second year after NE diagnosis. 
However, men showed no difference in number of deaths 
between the ﬁ   rst year and second year after diagnosis. 
These results suggest that there are sex differences in mor-
tality rates after infection with PUUV. Whether NE is a 
more lethal disease in women than men or causes increased 
mortality rates in men up to 2 years after diagnoses is un-
known.
The ﬁ  nding that the case-fatality rate for NE is associ-
ated with the age and sex of patients might have practical 
implications on healthcare issues. It may also indicate that 
age and sex should be considered predictive variables in 
clinical studies of hantavirus infections.
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Figure 1. Incidence of acute nephropathia epidemica (NE) and case-fatality rates, Sweden, 1997–2007. A) Age distribution for male and 
female patients with acute NE. B) Age distribution of case-fatality rates for all patients with acute NE. The Swedish Death Register was 
used to identify all deceased persons with a diagnosis of NE. Numbers of deaths during different periods after diagnoses were 21 (13 
male patients and 8 female patients) during the acute phase (<3 months after diagnoses), 7 (5 male patients and 2 female patients) after 
the acute phase (>3 months after diagnoses) but <1 year later, and 24 (19 male patients and 5 female patients) during the second year 
after diagnoses.
Figure 2. Overall standardized mortality ratios (SMRs) for male and 
female patients with a diagnosis of acute nephropathia epidemica 
(NE) and SMRs 3–12 mo after diagnosis, Sweden, 1997–2007.This study was supported by grants from the County of 
Västerbotten, the County Councils of Northern Sweden, the Med-
ical Faculty of Umeå University, the Royal Swedish Academy of 
Sciences, Åke Wibergs Stiftelse, the Swedish Society for Medical 
Research, and the Swedish Research Council.
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